NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating north of 80 at the beginning of a new price run.
Here Are 3 Keys For Successful Stock Investing
Is NewAmsterdam Pharma Stock A Buy?
NewAmsterdam Pharma stock broke out earlier, but has fallen back below the prior 26.35 entry from a consolidation. If a stock you're watching climbs above a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new base and breakout. Also understand that the latest pattern is a later-stage base, and such bases are more prone to failure.
The biotech company posted 0% earnings growth in its most recent report. Revenue increased 942%.
NewAmsterdam Pharma stock holds the No. 30 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Corcept Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
